Healthcare solutions provider Solventum (NYSE:SOLV) will be announcing earnings results this Thursday afternoon. Here’s what you need to know.
Solventum beat analysts’ revenue expectations by 2.7% last quarter, reporting revenues of $2.07 billion, up 2.7% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and a decent beat of analysts’ EPS estimates.
Is Solventum a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Solventum’s revenue to grow 1.9% year on year to $2.12 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.45 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Solventum has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 1.9% on average.
Looking at Solventum’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 3.1%, beating analysts’ expectations by 1.2%, and iRhythm reported revenues up 26.1%, topping estimates by 7.3%. CONMED traded up 1.8% following the results while iRhythm was also up 17.6%.
Read our full analysis of CONMED’s results here and iRhythm’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Solventum is down 4.2% during the same time and is heading into earnings with an average analyst price target of $84.86 (compared to the current share price of $73).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.